Clobetasol Propionate Cream USP 0.05% Recall for cGMP Deviations
Teligent Pharma is recalling all unexpired Clobetasol Propionate Cream USP 0.05% nationwide due to current Good Manufacturing Practice (cGMP) deviations related to discontinuation of the firm's stability study program.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses or injuries. The hazard is a cGMP deviation related to discontinuation of stability studies—a manufacturing/procedural issue rather than a confirmed product defect or contamination. No harm to patients has been reported.
Plain-English summary
Teligent Pharma, Inc. is recalling Clobetasol Propionate Cream USP, 0.05% (Emollient) in four package sizes: 15 grams (NDC 52565-094-15), 30 grams (NDC 52565-094-30), 45 grams (NDC 52565-094-45), and 60 grams (NDC 52565-094-60). A total of 105,200 tubes have been distributed nationwide in the USA and Puerto Rico.
The recall is issued because the manufacturer is discontinuing its stability study program, which constitutes a deviation from current Good Manufacturing Practice (cGMP) requirements. All products within their expiration dates are included in this recall.
Consumers who have received this medication should contact their pharmacist or healthcare provider before continuing use. Patients should not discontinue use of their medication without consulting their healthcare provider, as abrupt discontinuation could cause harm. The affected batches and expiration dates are listed with the FDA under recall number D-0671-2022.
The recalled product
- Product
- Clobetasol Propionate Cream USP, 0.05% (Emollient), packaged in a) 15 grams tube, NDC 52565-094-15; b) 30 grams tube, NDC 52565-094-30; c) 45 grams tube, NDC 52565-094-45; d) 60 grams tube, NDC 52565-094-60, Rx only, Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310.
- Manufacturer
- Teligent Pharma, Inc.
- Category
- Drug — Topical Corticosteroid
- Affected units
- 105,200
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (19)
- Batch: a) 15377
- Exp. 3/31/2022
- 15927
- Exp. 9/30/2022
- 16130
- Exp. 11/30/2022
- b) 15117
- Exp. 2/28/2022
- 16028
- 16945
- Exp. 5/31/2023
- c) 15377
- 16683
- Exp. 5/31/2022
- d) 15116
- 15117
- 16228
- 16348
- Exp. 1/31/2023
Distribution
Part of a larger recall action
This product is one of 37 recalled by Teligent Pharma, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 37 products in this recall →Related recalls
Same manufacturer · Teligent Pharma, Inc.
See all →- ModerateLidocaine Ointment USP 5% Recalled Due to cGMP Deviations
FDA (Drugs) · 2022-03-30
- ModerateDesonide Ointment Recalled Due to cGMP Deviations
FDA (Drugs) · 2022-03-30
- ModerateTriamcinolone Acetonide Ointment Recalled Due to cGMP Deviations
FDA (Drugs) · 2022-03-30
- HighDiflorasone Diacetate Ointment recalled due to discontinued stability studies
FDA (Drugs) · 2022-03-30
- ModerateDesoximetasone Ointment USP Recalled by Teligent Pharma
FDA (Drugs) · 2022-03-30
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09